Managing Severe Dyslipidemia with Combination Therapy

Introduction to Combination Therapy

• The American College of Cardiology recommends combining bempedoic acid, ezetimibe, fenofibrate, and omega-3 fish oil for managing severely elevated cholesterol and triglycerides, with ezetimibe specifically indicated for use with fenofibrate in mixed hyperlipidemia 1

FDA-Approved Combination Framework

• The FDA approves ezetimibe for combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia, providing the regulatory foundation for combining these agents when managing patients with both elevated cholesterol and triglycerides 2

Bempedoic Acid + Ezetimibe Component

• The fixed-dose combination of bempedoic acid 180mg and ezetimibe 10mg reduces LDL-C by approximately 35-38% when added to background therapy, according to the Journal of the American College of Cardiology 2, 3
• Bempedoic acid provides 15-25% LDL-C reduction as monotherapy and has demonstrated a 13% reduction in major adverse cardiovascular events in the CLEAR Outcomes trial, as reported in Circulation 4, 5

Fenofibrate Component for Triglycerides

• Fibrates are the drugs of choice for severe hypertriglyceridemia, reducing triglycerides by up to 50%, according to the European Heart Journal 6, 1
• Fenofibrate should be prescribed to reduce pancreatitis risk when triglycerides exceed 500 mg/dL, along with dietary fat restriction and alcohol avoidance, as recommended by the European Heart Journal 6, 1

Omega-3 Fatty Acid Considerations

• Prescription icosapent ethyl (IPE) 4g daily is recommended over standard fish oil for cardiovascular benefit if triglycerides remain 135-500 mg/dL with ASCVD or diabetes plus additional risk factors, according to Metabolism: Clinical and Experimental 1
• The REDUCE-IT trial demonstrated that icosapent ethyl added to statin therapy significantly reduces cardiovascular events in this population, as reported in Metabolism: Clinical and Experimental 1

Safety Monitoring and Timing Considerations

• Monitor liver function tests, uric acid levels, and creatine kinase as clinically indicated, and consider withdrawing ezetimibe if transaminases ≥3x ULN persist, as recommended by the Journal of the American College of Cardiology 2, 3
• Instruct patients about myalgia warning symptoms, though adverse muscle effects are rare with this combination, according to the European Heart Journal 6, 7

Treatment Algorithm for Severe Mixed Dyslipidemia

• Start bempedoic acid 180mg + ezetimibe 10mg fixed-dose combination daily, and add fenofibrate for triglycerides >500 mg/dL or 200-500 mg/dL with HDL-C ≤40 mg/dL, as recommended by the Journal of the American College of Cardiology and Metabolism: Clinical and Experimental 2, 1
• If triglycerides 135-500 mg/dL with ASCVD or diabetes plus risk factors, prescribe icosapent ethyl 4g daily, according to Metabolism: Clinical and Experimental 1

Critical Pitfalls to Avoid

• Do not use gemfibrozil in this combination—it significantly increases myopathy risk, as reported by the European Heart Journal 6, 7
• Do not use standard over-the-counter fish oil supplements expecting cardiovascular benefit—only prescription icosapent ethyl has proven outcomes data, according to Metabolism: Clinical and Experimental 1